c-Cbl 介导的 TRAIL 受体降解负责 TRAIL 耐药的早期阶段的发展。
c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance.
机构信息
Institute for Cancer Research, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
出版信息
Cell Signal. 2010 Mar;22(3):553-63. doi: 10.1016/j.cellsig.2009.11.012.
Abstract
We previously reported two modes of development of acquired TRAIL resistance: early phase and late phase [1]. In these studies, we observed that greater Akt activity and the expression of Bcl-xL were related mainly to the late phase of acquired TRAIL resistance. Recently we became aware of a possible mechanism of early phase TRAIL resistance development through internalization and degradation of TRAIL receptors (DR4 and DR5). Our current studies demonstrate that TRAIL receptors rapidly diminish at the membrane as well as the cytoplasm within 4h after TRAIL exposure, but recover completely after one or two days. Our studies also reveal that Cbl, a ubiquitously expressed cytoplasmic adaptor protein, is responsible for the rapid degradation of TRAIL receptors; Cbl binds to them and induces monoubiquitination of these receptors concurrent with their degeneration soon after TRAIL exposure, creating the early phase of acquired TRAIL resistance.
摘要
我们之前报道了获得性 TRAIL 抵抗的两种发展模式：早期阶段和晚期阶段[1]。在这些研究中，我们观察到 Akt 活性的增加和 Bcl-xL 的表达主要与获得性 TRAIL 抵抗的晚期阶段有关。最近，我们意识到 TRAIL 受体的内化和降解可能是早期 TRAIL 抵抗发展的一种机制。我们目前的研究表明，TRAIL 受体在 TRAIL 暴露后 4 小时内迅速从细胞膜和细胞质中消失，但在 1 或 2 天后完全恢复。我们的研究还揭示了 Cbl，一种广泛表达的细胞质衔接蛋白，负责 TRAIL 受体的快速降解；Cbl 与它们结合，并在 TRAIL 暴露后不久诱导这些受体的单泛素化及其退化，从而产生获得性 TRAIL 抵抗的早期阶段。
相似文献
1
c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance.c-Cbl 介导的 TRAIL 受体降解负责 TRAIL 耐药的早期阶段的发展。
Cell Signal. 2010 Mar;22(3):553-63. doi: 10.1016/j.cellsig.2009.11.012.
2
Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.蟾毒灵下调 Cbl-b 导致乳腺癌细胞中 DR4/DR5 的上调和 TRAIL 诱导的细胞凋亡敏感性增加。
J Cancer Res Clin Oncol. 2012 Aug;138(8):1279-89. doi: 10.1007/s00432-012-1204-4. Epub 2012 Mar 24.
3
c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment.衔接蛋白 c-Cbl 作为 Src 在 TRAIL 处理过程中诱导激活 PI3K-Akt 信号转导通路的中介物。
Cell Signal. 2010 Mar;22(3):377-85. doi: 10.1016/j.cellsig.2009.10.007.
4
DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells.DR5-Cbl-b/c-Cbl-TRAF2 复合物通过促进 TRAF2 介导的半胱天冬酶-8 多泛素化来抑制胃癌细胞中 TRAIL 诱导的细胞凋亡。
Mol Oncol. 2017 Dec;11(12):1733-1751. doi: 10.1002/1878-0261.12140. Epub 2017 Oct 27.
5
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.c-Cbl shRNA 表达的腺病毒通过增加 DR4/5 使前列腺癌细胞株 DU-145 对 TRAIL 诱导的凋亡敏感。
Cancer Gene Ther. 2013 Feb;20(2):82-7. doi: 10.1038/cgt.2012.88. Epub 2013 Jan 11.
6
Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells.通过 GODZ 将 TRAIL 受体 1 靶向细胞表面来调节肿瘤细胞对 TRAIL 的敏感性。
Cell Death Differ. 2012 Jul;19(7):1196-207. doi: 10.1038/cdd.2011.209. Epub 2012 Jan 13.
7
TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex.TRAIL/MEKK4/p38/HSP27/Akt 生存信号通路受Src/CIN85/c-Cbl 复合物的双向调节。
Cell Signal. 2013 Jan;25(1):372-9. doi: 10.1016/j.cellsig.2012.10.010. Epub 2012 Oct 23.
8
Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.DR4、DR5的膜表达以及半胱天冬酶-8水平（而非Mcl-1）决定了人骨髓瘤细胞对Apo2L/TRAIL的敏感性。
Exp Cell Res. 2007 Jul 1;313(11):2378-88. doi: 10.1016/j.yexcr.2007.03.018. Epub 2007 Mar 30.
9
TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells.Cbl-b 调控的脂筏内 EGFR 重分布激活 TRAIL 受体拮抗 TRAIL 诱导的胃癌细胞凋亡。
Eur J Cancer. 2012 Nov;48(17):3288-99. doi: 10.1016/j.ejca.2012.03.005. Epub 2012 Mar 27.
10
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.DR4特异性TRAIL变体在胰腺癌中比野生型TRAIL更有效。
Cancer Biol Ther. 2014;15(12):1658-66. doi: 10.4161/15384047.2014.972183.
引用本文的文献
1
TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.肿瘤坏死因子相关凋亡诱导配体：非凋亡信号。
Cells. 2024 Mar 16;13(6):521. doi: 10.3390/cells13060521.
2
Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells.刘易斯糖脂作为癌细胞中 TRAIL 敏感性的关键决定因素。
Oncogene. 2022 Sep;41(38):4385-4396. doi: 10.1038/s41388-022-02434-3. Epub 2022 Aug 15.
3
Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.死亡受体DR4和DR5会发生自发的和配体介导的内吞作用及再循环，而与癌细胞对TRAIL的敏感性无关。
Front Cell Dev Biol. 2021 Sep 30;9:733688. doi: 10.3389/fcell.2021.733688. eCollection 2021.
4
Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.死亡受体4的下调与EGFR突变型肺癌对EGFR靶向治疗的阳性反应及预后改善密切相关。
Theranostics. 2021 Feb 15;11(8):3964-3980. doi: 10.7150/thno.54824. eCollection 2021.
5
Dexamethasone Inhibits TRAIL-Induced Apoptosis through c-FLIP(L) Upregulation and DR5 Downregulation by GSK3β Activation in Cancer Cells.地塞米松通过激活GSK3β上调c-FLIP(L)和下调DR5来抑制TRAIL诱导的癌细胞凋亡。
Cancers (Basel). 2020 Oct 9;12(10):2901. doi: 10.3390/cancers12102901.
6
Upregulation of DR5 and Downregulation of Survivin by IITZ-01, Lysosomotropic Autophagy Inhibitor, Potentiates TRAIL-Mediated Apoptosis in Renal Cancer Cells via Ubiquitin-Proteasome Pathway.溶酶体促效自噬抑制剂IITZ-01上调DR5并下调Survivin，通过泛素-蛋白酶体途径增强TRAIL介导的肾癌细胞凋亡。
Cancers (Basel). 2020 Aug 21;12(9):2363. doi: 10.3390/cancers12092363.
7
Ischemic Preconditioning Upregulates Decoy Receptors to Protect SH-SY5Y Cells from OGD Induced Cellular Damage by Inhibiting TRAIL Pathway and Agitating PI3K/Akt Pathway.缺血预处理上调诱饵受体，通过抑制TRAIL途径和激活PI3K/Akt途径保护SH-SY5Y细胞免受氧糖剥夺诱导的细胞损伤。
Mol Neurobiol. 2020 Sep;57(9):3658-3670. doi: 10.1007/s12035-020-01978-3. Epub 2020 Jun 20.
8
Inflammatory bowel disease-associated ubiquitin ligase RNF183 promotes lysosomal degradation of DR5 and TRAIL-induced caspase activation.炎症性肠病相关泛素连接酶 RNF183 促进 DR5 和 TRAIL 诱导的半胱天冬酶激活的溶酶体降解。
Sci Rep. 2019 Dec 30;9(1):20301. doi: 10.1038/s41598-019-56748-6.
9
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.二硫键破坏剂激活肿瘤坏死因子家族相关凋亡诱导配体/死亡受体5通路。
Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019.
10
Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells.靶向 KPNB1 通过调节胶质母细胞瘤细胞中的 DR5、Mcl-1 和 FLIP 克服 TRAIL 耐药性。
Cell Death Dis. 2019 Feb 11;10(2):118. doi: 10.1038/s41419-019-1383-x.
本文引用的文献
1
Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.肿瘤坏死因子相关凋亡诱导配体（TRAIL）诱导的凋亡不需要受体介导的内吞作用。
J Biol Chem. 2007 Apr 27;282(17):12831-41. doi: 10.1074/jbc.M700438200. Epub 2007 Feb 27.
2
Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.获得性肿瘤坏死因子相关凋亡诱导配体抗性的两种发展模式的证据。Bcl-xL的参与。
J Biol Chem. 2007 Jan 5;282(1):319-28. doi: 10.1074/jbc.M608065200. Epub 2006 Nov 15.
3
Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism.腺病毒14.7K抑制肿瘤坏死因子受体1内化作为一种新的免疫逃逸机制。
J Clin Invest. 2006 Nov;116(11):2901-13. doi: 10.1172/JCI23771. Epub 2006 Oct 5.
4
The role of receptor internalization in CD95 signaling.受体内化在CD95信号传导中的作用。
EMBO J. 2006 Mar 8;25(5):1009-23. doi: 10.1038/sj.emboj.7601016. Epub 2006 Feb 23.
5
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis.瘦素受体OB-Ra的泛素化调节其网格蛋白介导的内吞作用。
EMBO J. 2006 Mar 8;25(5):932-42. doi: 10.1038/sj.emboj.7600989. Epub 2006 Feb 16.
6
Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins.衔接蛋白APS家族中一种新型Cbl磷酸酪氨酸识别基序的结构特征
J Biol Chem. 2005 May 13;280(19):18943-9. doi: 10.1074/jbc.M414157200. Epub 2005 Feb 28.
7
Recognition of the tryptophan-based endocytosis signal in the neonatal Fc Receptor by the mu subunit of adaptor protein-2.衔接蛋白2的μ亚基对新生儿Fc受体中基于色氨酸的内吞信号的识别。
J Biol Chem. 2005 Feb 25;280(8):7309-16. doi: 10.1074/jbc.M410752200. Epub 2004 Dec 14.
8
Targeting death receptors in cancer with Apo2L/TRAIL.利用Apo2L/TRAIL靶向癌症中的死亡受体
Curr Opin Pharmacol. 2004 Aug;4(4):333-9. doi: 10.1016/j.coph.2004.02.006.
9
c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes.c-Cbl介导的泛素化是表皮生长因子受体从早期内体中排出所必需的。
J Biol Chem. 2004 Aug 27;279(35):37153-62. doi: 10.1074/jbc.M403210200. Epub 2004 Jun 21.
10
Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.化疗药物和钙蛋白酶抑制剂I通过不同机制克服对TRAIL的获得性耐药。
Mol Ther. 2004 May;9(5):666-73. doi: 10.1016/j.ymthe.2004.02.007.
Zotero 插件